Phase 1 Clinical Trial MPC-2130 Treatment of Blood Cancers / Refractory Cancer

NCT00387153 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

8

Enrollment

INDUSTRY

Sponsor class

Stopped Last subject enrolled experienced bradycardia; study was terminated by Sponsor.

Conditions

Cancer

Interventions

DRUG: MPC-2130

Sponsor

Myriad Therapeutics, Inc.